

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068741 A1

(51) International Patent Classification⁷: **C07D 209/12,**
A61K 31/404

(21) International Application Number: **PCT/JP02/01192**

(22) International Filing Date: 13 February 2002 (13.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **MEIJI DAIRIES CORPORATION** [JP/JP]; 1-2-10, Shinsuna, Koto-Ku, Tokyo 136-8908 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LUU, Bang** [FR/FR]; CNRS, Université Louis Pasteur, Centre de Neurochimie, 5, rue Blaise Pascal, F-67084 Strasbourg (FR). **COOWAR, Djalil** [FR/FR]; CNRS, Université Louis Pasteur, Centre de Neurochimie, 5, rue Blaise Pascal, F-67084 Strasbourg (FR). **YAMADA, Masashi** [JP/JP]; Meiji Dairies Corporation, Development Section, Pharmaceuticals Dept., 1-2-10,

Shinsuna, Koto-ku, Tokyo 136-8908 (JP). **SUMA, Yukie** [JP/JP]; Meiji Dairies Corporation, Development Section, Pharmaceuticals Dept., 1-2-10, Shinsuna, Koto-ku, Tokyo 136-8908 (JP). **SUZUKI, Hiroto** [JP/JP]; Meiji Dairies Corporation, Development Section, Pharmaceuticals Dept., 1-2-10, Shinsuna, Koto-ku Tokyo 136-8908 (JP).

(74) Agent: **THE PATENT CORPORATE BODY ARUGA PATENT OFFICE**; Kyodo Bldg., 3-6, Nihonbashiningyocho 1-chome, Chuo-ku Tokyo 103-0013 (JP).

(81) Designated States (national): CA, US.


(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **INDOLE DERIVATIVES SUBSTITUTED WITH LONG-CHAIN ALCOHOLS AND MEDICAMENTS CONTAINING THEM**



(57) Abstract: Provided is an indole long-chain alcohol represented by the following formula (I): wherein R¹, R², R³ and R⁴ each independently represents hydrogen atom, methyl group, acetyl group or hydroxyl group and n stands for a number from 0 to 20; and a medicament comprising the same. The compound (I) has an excellent nerve growth promoting effect, as well as antioxidative and anti-tumor effects, and thus is useful as a preventive and/or therapeutic drug for cerebral diseases such as dementia or malignant tumors such as cerebral tumor.

WO 03/068741 A1

DESCRIPTION

INDOLE DERIVATIVES SUBSTITUTED WITH LONG-CHAIN ALCOHOLS AND MEDICAMENTS
CONTAINING THEM

5 **Technical Field**

The present invention relates to an indole long-chain alcohol which exhibits an excellent nerve growth promoting effect and potent antioxidative and antitumor effects, and is therefore useful as a preventive and/or therapeutic agent for cerebral diseases typified by dementia or malignant tumors such as brain tumor; and a medicament containing the compound.

Background Art

15 It is considered that the main lesion of Alzheimer's disease is degeneration and defluvium of cholinergic neurons. At present, a cholinesterase inhibitor or a muscalinic receptor agonist is used for the treatment of said disease. Such a medicament alleviates dementia
20 symptomatically but cannot stop or retard the progress of the morbidity. There has also been made an attempt to treat Alzheimer's disease by administering a nerve growth factor (NGF) into the brain. NGF is expected to suppress degeneration and defluvium of neurons due to its neuron
25 growth action, thereby terminating or retarding the

progress of dementia. However, since NGF is a protein having a molecular weight of 12,000, it cannot pass through the blood-brain barrier and its administration route is confined only to intraventricular administration, which is not practical for the treatment of human beings. If there is such compound that exhibits an NGF-like action and has a molecular weight low enough to pass through the blood-brain barrier or such compound that can enhance the synthesis of NGF in the brain, it will be promising as a remedy effective for treating Alzheimer's dementia.

Based on such an idea, a substance which promotes and/or reinforces production of NGF has been searched, and it has been proved that long-chain aliphatic alcohols such as n-hexacosanol stimulate nerve growth factor *in vitro* and can pass through the blood-brain barrier *in vivo* (Japanese Patent Application Laid-Open No. 502167/1992).


Disclosure of the Invention

Accordingly, an object of the present invention is to provide a medicament comprising a compound which is orally administrable, readily transferred into the brain, and permits extension of neurite in the brain or activates the synthesis and secretion of NGF.

The present inventors have synthesized a long-chain alcohol derivative having an indole skeleton and

investigated its pharmacological action. As a result, it has been found that an indole long-chain alcohol represented by the formula (I) shown below exhibits an excellent nerve growth promoting effect and potential antioxidative and anti-tumor effects, and is therefore useful as a preventive and/or therapeutic drug for cerebral diseases such as dementia or malignant tumors such as cerebral tumor, to complete the present invention.

In one aspect of the present invention, there is thus provided an indole long-chain alcohol represented by the following formula (I):



wherein R^1 , R^2 , R^3 and R^4 each independently represents a hydrogen atom, a methyl group, an acetyl group or a hydroxyl group and n stands for a number from 0 to 20.

In another aspect of the present invention, there is also provided a medicine comprising the compound of the formula (I) as an effective ingredient.

In a further aspect of the present invention, there is also provided a nerve growth promoting agent comprising the compound of the formula (I) as an effective ingredient.

In a still further aspect of the present invention, there is also provided a preventive and/or therapeutic drug for dementia and/or malignant tumors, which comprises the compound of the formula (I) as an effective ingredient.

5 In a still further aspect of the present invention, there is also provided a medical composition comprising the compound of the formula (I) together with a pharmaceutically acceptable carrier.

(In a still further aspect of the present invention, there is also provided use of the compound of the formula (I) for the manufacture of a medicament.

In a still further aspect of the present invention, there is also provided use of the compound of the formula (I) for the manufacture of a nerve growth promoting agent.

15 In a still further aspect of the present invention, there is also provided use of the compound of the formula (I) for the manufacture of a preventive and/or therapeutic drug for dementia and/or malignant tumor.

(In a still further aspect of the present invention, there is also provided a method for treating cerebral diseases and/or malignant tumors which comprises administering an effective amount of the compound of the formula (I) to a patient in need thereof.

25 **Brief Description of the Drawings**

FIG. 1 illustrates the effect of the compounds of the invention on neurite outgrowth; and FIG. 2 illustrates the effect of the compounds of the invention on preventing hemolysis of human blood cells induced by free radicals.

5


Best Mode for Carrying Out the Invention

In the formula (I), R^1 , R^2 , R^3 and R^4 can be any of the above-described groups and are particularly preferably hydrogen atom. n stands for a number from 0 to 20, preferably 2 to 18, more preferably 6 to 16, and particularly preferably 8 to 14.

10

The compound (I) may be in the form of a hydrate. There are many isomers in the compound (I) and these isomers are also embraced in the present invention.

The invention compound (I) can be prepared, for example, in accordance with the following reaction scheme:



wherein Ar represents an aromatic hydrocarbon group, X^1 and X^2 each represents a halogen atom, R^5 represents a hydroxyl-protecting group and R^1 , R^2 , R^3 , R^4 and n have the same

meanings as described above.

Specifically, an indole-3-carboxyaldehyde (A) is reacted with an arylsulfonyl halide to give Compound (B), which is in turn reacted with Compound (C) according to Wittig reaction to give Compound (D), and then Compound (D) is halogenated to remove the hydroxyl-protecting group therefrom to give Compound (E), and then the amino-protecting group in the Compound (E) is removed to obtain the compound(I) of the invention.

As the arylsulfonyl halide, p-methoxybenzenesulfonyl chloride can be illustrated. The reaction between the indole-3-carboxyaldehyde (A) and the arylsulfonyl halide is preferably conducted in the presence of an alkali such as sodium hydroxide.

As the hydroxyl-protecting group (R^5) in the Compound (C) used in the Wittig reaction, preferred is a group removable by hydrogenation, such as, for example, benzyl group. The Wittig reaction is preferably conducted by reacting Compound (C) with n-butyl lithium, followed by reaction with potassium t-butoxide and then with Compound (B).

Hydrogenation of Compound (D) is preferably conducted by reacting it with hydrogen in the presence of, for example, a palladium catalyst. In the subsequent reaction for eliminating the arylsulfonyl group, an amalgam

hydroxide and sodium hydrogenphosphate are preferably used.

Since the resulting compound (I) exhibits an excellent nerve growth promoting effect and potent antioxidative and antitumor effects, and has a molecular weight low enough to pass through the blood-brain barrier, it is useful as a preventive and/or therapeutic drug for cerebral diseases typified by dementia of animals including human being and malignant tumors such as cerebral tumor.

The medicament according to the present invention can be-administered either orally or parenterally (such as intramuscular, subcutaneous, intravenous or suppository). In preparing these dosage forms, it is preferred to use a medical composition containing the compound (I) of the invention and a pharmaceutically acceptable carrier. Oral preparations can be formulated into tablets, coated tablets, granules, capsules, solutions, syrups, elixirs, or oily or aqueous suspensions in a manner known per se in the art after adding to the compound (I) an excipient and, if necessary, a binder, a disintegrator, a lubricant, a colorant and/or a corrigent. Examples of the excipient include lactose, corn starch, sucrose, glucose, sorbitol and crystalline cellulose. Examples of the binder include polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropyl cellulose, hydroxypropyl starch and polyvinyl

pyrrolidone. Examples of the disintegrator include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextran and pectin; and examples of the lubricant include magnesium
5 stearate, talc, polyethylene glycol, silica and hardened vegetable oil. As the colorant, pharmaceutically acceptable ones can be used. Examples of the corrigent include cocoa powder, menthol, aromatic acid, peppermint oil, camphor and cinnamon powder. The tablets and granules
10 may be applied with sugar coating, gelatin coating or the like as needed.

The dose of the medicine of the invention varies depending on the disease to be treated, administration route, symptoms and weight of a patient. For a human
15 adult, the daily dose of the compound (I) will be usually within a range of from 0.001 to 1000 mg/day, and preferably from 0.1 to 100 mg/day. This daily dose is administered once a day or in 2 to 4 portions a day.

20 Examples

The present invention will be hereinafter described in further detail by way of examples. It should however be borne in mind that the present invention is not limited to or by these examples.

25

Reference Example 1

3-indolecarboxyaldehyde (1.003 g, 6.91 mmol) was dissolved in 20 mL of dry dichloromethane, and then sodium hydroxide (410 mg, 10.24 mmol) was added thereto. After allowing to stand for 15 minutes at room temperature, the resulting mixture was added with 4-methoxybenzenesulfonyl chloride (2.112 g, 10.22 mmol) and was allowed to stand again at room temperature for 12 hours. To the reaction mixture, 100mL of ammonium chloride was added and the mixture was extracted with 100 mL of ethyl acetate three times. The combined organic layer was washed with saline, dried over anhydrous magnesium sulfate and then concentrated. The residue was recrystallized to give 1-(4-methoxybenzensulfonyl)-3-indolecarboxyaldehyde as pearl-like pink crystals.

Melting point: 138 to 139°C

¹H-NMR (200 MHz): 3.81(s, 3H, H-9), 6.94(d, J=9.1Hz, 2H, H-3", 5"), 7.32-7.45(m, 2H, H-5, 6), 7.91(d, J=9.1Hz, 2H, H-2", 6"), 7.87-7.96(m, 1H, H-4), 8.23(s, 1H, H-2), 8.25(dd, J=6.9Hz, J=2.7Hz, 1H, H-7), 10.09(s br, 1H, H-8).

¹³C-NMR (50 MHz): 55.81(C-9), 113.25(C-7), 114.94(C-3", 5"), 122.26(C-3), 122.60(C-4, 6), 125.01(C-5), 126.27(C-2", 6"), 128.63(C-3'), 129.61(C-7'), 135.23(C-1"), 136.24(C-2), 164.54(C-4"), 185.34(C-8).

Reference Example 2

A solution of 15-benzyloxypentadecyltriphenyl phosphonium bromide (755 mg, 1.14 mmol) dissolved in 10 ml of tetrahydrofuran (THF) was added dropwise to n-butyl lithium (1.5M in hexane, 0.8 mL, 1.20 mmol) at -78°C in an argon gas atmosphere. After reaction at room temperature for 15 minutes, potassium t-butoxide (131 mg, 1.16 mmol) was added to the reaction mixture at 0°C. The resulting solution was then allowed to stand at room temperature for 15 minutes. After the solution was cooled again to -78°C, a THF solution of 1-(4-methoxybenzenesulfonyl)-3-indolecarboxyaldehyde (307 mg, 0.97 mmol) was slowly added to the solution. The resulting mixture was allowed to stand at -78°C for 1 hour, and then allowed to stand at 0°C for 1.5 hours. Ammonium chloride (50 mL) was added to the mixture and the resulting mixture was extracted three times with 60 ml of ethyl ether. The combined organic layer was washed with saline, dried over anhydrous magnesium sulfate and then concentrated. The residue was purified by chromatography on a silica gel column to give 3-(16-benzyloxyhexadecenyl)-1-(4-methoxybenzenesulfonyl)indole as a white solid.

¹H-NMR (200 MHz), .: 1.26(s br, 20H, H-12 to H-21), 1.46-1.65(m, 4H, H-11, 22), 2.32(m, 2H, H-10), 3.47(t, J=6.6Hz, 2H, H-23), 3.77(s, 3H, H-25), 4.51(s, 2H, H-24),

5.82(dt, J=11.1Hz, J=6.9Hz, 1H, H-9), 6.40(d, J=11.1Hz, 1H, H-8),
6.86(d, J=8.7Hz, 2H, H-3'', 5''), 7.21-7.36(m, 7H, H-2'' to H-6'',
H-5, 6), 7.51(s, 1H, H-2), 7.53(d, J=6.9Hz, 1H, H-4),
7.82(d, J=8.7Hz, 2H, H-2'', 6''), 7.99(d, J=7.6Hz, 1H, H-7).

5 ¹³C-NMR (500 MHz) .: 26.35(C-10), 29.83(C-11 to C-22),
55.75(C-25), 70.70(C-23), 72.99(C-24), 113.74(C-7),
114.56(C-9), 117.58(C-3'', s5''), 119.41(C-3), 119.71(C-5),
123.31(C-4), 123.58(C-6), 124.92(C-2'', 6''), 127.61(C4''),
(127.74(C-3'', 5''), 128.49(C-2'', 6''), 129.18(C-8),
10 129.90(C-3'), 131.25(C-7'), 134.79(C-1''), 135.02(C-2),
138.92(C-1''), 163.92(C-4'').

In a similar manner to Reference Examples 1 and 2, 3-
(10-benzyloxydecenyl)-1-(4-methoxybenzenesulfonyl)indole
(yield: 70%), 3-(12-benzyloxydodecenyl)-1-(4-methoxy-
15 benzenesulfonyl)indole (yield: 87%) and 3-(14-benzyloxy-
tetradecenyl)-1-(4-methoxybenzenesulfonyl)indole (yield:
88%) were obtained.

Reference Example 3

20 3-(16-benzyloxyhexadecenyl)-1-(4-methoxybenzen-
sulfonyl)indole (530 mg, 0.86 mmol) was dissolved in 25 mL
of ethanol and added to palladium supported on activated
charcoal (5%, 50 mg). The resulting mixture was allowed to
stand at room temperature for 3 hours under 1 atmospheric
25 pressure of hydrogen. After filtration, the reaction

mixture was extracted with ethyl ether. The organic layer was concentrated under reduced pressure. The residue was purified by flash chromatography to give 3-(16-hydroxyhexadecyl)-1-(4-methoxybenzenesulfonyl)indole as a white solid (417 mg, 92%).

¹H-NMR (200 MHz) .: 1.26(s br, 24H, H-10 to H-21), 1.62(m, 4H, H-9, 22), 2.63(t, J=7.4Hz, 2H, H-8), 3.64(t, J=6.4Hz, 2H, H-23), 3.77(s, 3H, H-24), 6.85(d, J=8.8Hz, 2H, H-3", 5"), 7.25(m, 2H, H-5, 6), 7.29(s, 1H, H-2), 7.47(d, J=6.6Hz, 1H, H-4), 7.79(d, J=8.8Hz, 1H, H-2", 6"), 7.97(d, J=7.6Hz, 1H, H-7).

¹³C-NMR (50 MHz) .: 24.93(C-21), 25.80(C-9), 28.94(C-20), 29.70(C-10 to C-19), 32.87(C-8), 55.63(C-24), 63.14(C-23), 113.81(C-7), 114.36(C-9), 119.54(C-3", 5"), 122.64(C-4), 122.89(C-6), 123.66(C-3), 124.50(C-5), 128.99(C-2", 6"), 129.99(C-3'), 131.31(C-7'), 134.85(C-1"), 135.44(C-2), 163.60(C"-4).

In a similar manner to Reference Example 3, 3-(10-hydroxydecyl)-1-(4-methoxybenzenesulfonyl)indole (yield: 92%), 3-(12-hydroxydodecyl)-1-(4-methoxybenzenesulfonyl)-indole (yield: 92%) and 3-(14-hydroxytetradecyl)-1-(4-methoxybenzenesulfonyl)indole (yield: 93%) were obtained.

Example 1

To a solution of 3-(16-hydroxyhexadecyl)-1-(4-

methoxybenzenesulfonyl)indole (400 mg, 0.72 mmol) dissolved in 20 ml of dry methanol were added disodium hydrogen-phosphate (205 mg, 1.44 mmol) and amalgam chloride (6%, 4g) at 0°C under argon gas. After the resulting mixture was allowed to stand at room temperature for 12 hours, 50 mL of ammonium chloride was added thereto. The resulting mixture was extracted three times with 60 ml of ethyl ether. The combined organic layer was washed with saline, dried over anhydrous magnesium sulfate and then concentrated. The residue was purified by chromatography on a silica gel column to give 3-(16-hydroxyhexadecyl)indole (Compound 1) as a white solid (204 mg, 75%).

Melting point: 79 to 80°C

¹H-NMR (200 MHz) : 1.27(s br, 24H, H-10 to H-21), 1.57(m, 2H, H-22), 1.72(m, 2H, H-9), 2.76(t, J=7.6Hz, 2H, H-8), 3.64(t, J=6.4Hz, 2H, H-23), 6.97(s, 1H, H-2), 7.15(m, 2H, H-5, 6), 7.35(d, J=7.6Hz, 1H, H-4), 7.62(d, J=7.6Hz, 1H, H-7), 7.93(s br, 1H, H-1)

¹³C-NMR (50MHz) : 25.30(C-21), 25.89(C-9), 29.83(C-10 to C-20), 30.32(C-8), 32.97(C-22), 63.26(C-23), 111.15(C-7), 117.38(C-3), 119.15(C-4, 6), 121.12(C-5), 121.94(C-2), 127.79(C-3'), 136.52(C-7')

IR (KBr): 3416(s br, O-H, N-H), 3049(w, =C-H), 2916, 2849(s, C-H), 1638, 1618(m, C=C), 1474, 1457(m, C-H), 1061(w, C-O), 741(m, C-H)

UV (acetonitrile): .max: 203 nm (. 18864), 222 nm (.
27571), 281 nm (. 5880)

MS (EI): 357.3 (M^+ ,37), 144.2($C_{10}H_{10}N$,4), 130.3(C_9H_8N ,100)

In a similar manner to Example 1, the following
5 compounds were obtained.

- 3-(2-hydroxyethyl)indole (liquid) (Compound 2)
- 3-(10-hydroxydecyl)indole (melting point: 55 to 56°C)
(Compound 3)
- 3-(11-hydroxyundecyl)indole (melting point: 60 to 61°C)
10 (Compound 4)
- 3-(12-hydroxydodecyl)indole (melting point: 66 to 67°C)
(Compound 5)
- 3-(14-hydroxytetradecyl)indole (melting point: 72 to
73°C) (Compound 6)

15
Test Example 1 (Effect on neurite outgrowth and neuron
survival)

This experiment was conducted in accordance with the
method of Luu, et al. (C. Girlanda-Junges, F. Keyling-
20 Bilger, G. Schemitt & B. Luu, "Effect of Cyclohexenonic
Long Chain Fatty Alcohols on Neurite Outgrowth. Study on
Structure-Activity Relationship", Tetrahedron, 54, 7735-
7748(1998)). Fetal rat neurons in primary cultures were
treated with Compound 1 at the concentrations of 10^{-6} and
25 10^{-7} M, followed by incubation for 3 days. As illustrated

in FIG. 1, the proportion of the neurons with neurites of 50 μ m or longer was found to be higher in the treated group than in the control group, which clearly shows that Compound 1 has a potent neurite extension effect.

5

Test Example 2 (Preventive effect on hemolysis in human blood cells induced by free radicals)

An experiment was conducted in accordance with the method of D. Blache. FASEB J. et al. (E. Bourdon, N. Loreau & D. Blache. FABES J. "Glucose and free radicals impair the antioxidant properties of serum albumin", 13, 233-244(1999)). The time required for 50% hemolysis (HT₅₀) was measured and the extension of the time required for HT₅₀ compared with that of a control group was plotted on a graph. In this experiment, Vitamin E was employed as a positive control. As illustrated in FIG. 2, the compounds of the invention (Compounds 1, 2 and 4) extended HT₅₀, thus exhibiting preventive effect on hemolysis. Particularly, Compound 4 exhibited a strong effect.

20

Test Example 3 (Induction of differentiation and apoptosis of neuroblastoma cells)

Human neuroblastoma cells, Lan-1 (Lan-1: a human neuroblastoma cell line with M1 and M2 muscarinic receptors conjugated with intracellular Ca²⁺) were used to

25

investigate the effects of the present compounds on the induction of proliferation, differentiation and apoptosis. As shown in Table 1, the present compounds (Compounds 1, 3 and 4) exhibited stronger effects on induction of

5 differentiation or apoptosis of neuroblastoma cells rather than on proliferation of the cells.

Table 1

	Concen- -tration μ M	Day 1			Day 2			Day 5			Day 7		
		Prolife- -ration	Differen- -tiation	Apop- -tosis	Prolife- -ration	Differen- -tiation	Apop- -tosis	Prolife- -ration	Differen- -tiation	Apop- -tosis	Prolife- -ration	Differen- -tiation	Apop- -tosis
Control		+	-	-	++	-	-	++	-	+/-	++	-	+/-
Comp'd 3	0.1	+	+	-	+	+	-	+	-	+/-	++	+/-	+/-
	10	+/-	+++	-	+/-	++	+	+/-	++	+	+/-	+++	+
	100	-	+	++	+/-	+	++	+/-	+++	++			+++
Comp'd 4	0.1	++	-	-	+	+	-	+/-	+/-	-	++	+/-	-
	10	+	++	-	+/-	++	+	+/-	++	-	+/-	++	+/-
	100	+/-	+	+++	-	-	+++	+	+++	+			+++
Comp'd 1	0.1	+	+/-	-	++	+/-	-	+/-	+/-	-	+/-	+	+/-
	10	+	++	+/-	+	+++	+/-	+/-	+++	++	+/-	+++	++
	100	+/-	+++	+	-	+++	+	-	+	+++	-	++	+++


++++: Extremely strongly stimulated (reinforced).
 +++ : Very strongly stimulated (reinforced).
 ++ : Strongly stimulated (reinforced).
 + : Stimulated (reinforced).
 +/- : No change.
 - : Decreased (weakened).

Industrial Applicability

The present compound (I) has an excellent nerve growth promoting effect, an antioxidative effect and an antitumor effect and is therefore useful as a preventive and/or
5 therapeutic drug for cerebral diseases such as dementia or malignant tumors such as cerebral tumor.

Claims

1. An indole long-chain alcohol represented by the following formula (I):



5 wherein R^1 , R^2 , R^3 and R^4 each independently represents a hydrogen atom, a methyl group, an acetyl group or a hydroxyl group and n stands for a number from 0 to 20.

2. A medicament comprising the compound of claim 1 as an effective ingredient.

10 3. A nerve growth promoting agent comprising the compound of claim 1 as an effective ingredient.

4. A preventive and therapeutic drug for dementia and/or malignant tumors comprising the compound of claim 1 as an effective ingredient.

15 5. A medical composition comprising the compound of claim 1 together with a pharmaceutically acceptable carrier.

6. Use of the compound of claim 1 for the manufacture of a medicament.

20 7. Use of the compound of claim 1 for the manufacture of a nerve growth promoting agent.

8. Use of the compound of claim 1 for the manufacture of a preventive and therapeutic drug for dementia and/or malignant tumors.

5 9. A method for treating a cerebral disease and/or malignant tumor which comprises administering an effective amount of the compound of claim 1 to a patient in need thereof.

FIG. 1





FIG. 2



INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 02/01192

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D209/12 A61K31/404

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 197 479 A (JOHNSON HERBERT E) 27 July 1965 (1965-07-27) column 1, line 40-53 -column 2, line 15-22; examples 1-4,7-9 ---	1
X	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 143517 XP002198689 abstract & KOO ET AL.: J.ORG.CHEM., vol. 24, 1959, page 179-183 --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

13 May 2002

Date of mailing of the international search report

06/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Gavrilu, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 02/01192

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	V.ESPAMER, R.FERRINI, A.GLAESSER: "A note on the oxidative deamination of isomers of 5-hydroxytryptamine and other indolealkylamine" J.PHARM.PHARMACOL., vol. 12, no. 5-9, 1960, pages 761-764, XP001070895 abstract	1
X	C.A.DEMERSON, L.G.HUMBER, A.H.PHILIPP: "Etodolic Acid and related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-ac etic Acid" J.MED.CHEM., vol. 19, no. 3, 1976, page 391-395 XP000940626 schemes 1;2 example E	1
X	L.G.HUMBER; C.A.DEMERSON; A.A.ASSELIN: "A novel class of potential antidepressants 1-aminoalkyl-1,3,4,9-tetrahydropyrano[3,4-b indoles" EUR.J.MED.CHEM.CHIM.THER., vol. 10, no. 3, 1975, page 215-220 XP001070868 scheme 1-compound 1 page 218, column 1	1
X	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 134161 XP002198690 abstract & J.MANSKE: J.AMER.CHEM.SOC., vol. 52, 1930, page 5029-5031	1
X	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 1527688, 1527673 XP002198691 abstract & CHEMICAL ABSTRACTS, vol. 74, no. 3, 1971 Columbus, Ohio, US; abstract no. 12933x, & I.I.GRANDBERG; T.P.MOSKVINA: KHIM.GETEROTSIKL.SOEDIN., vol. 6, 1970, page 942-944	1

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 02/01192

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A.J.GREENBERG;R.KETCHAM: "Determination of Urinary Indolic Metabolites" J.PHARM.SCI., vol. 67, no. 1, 1978, page 478-480 XP001070899 compounds IV and V ----	1
X	GB 778 823 A (UPJOHN CO) 10 July 1957 (1957-07-10) page 4, line 94-102; examples 1-3,11,17 ----	1
X	FR 2 499 987 A (KAWAKEN FINE CHEMICALS CO) 20 August 1982 (1982-08-20) figure 1; examples 1,12-14 ----	1
X	EP 0 548 813 A (SQUIBB BRISTOL MYERS CO) 30 June 1993 (1993-06-30) page 21, line 10-20; example 10 ----	1
X	WO 90 14084 A (COHEN MICHAEL) 29 November 1990 (1990-11-29) page 6, line 15-25; claim 2 ----	1
Y	TETRAHEDRON, vol. 54, 1998, page 7735-7748 XP002198688 cited in the application page 7740-42; figure 1 ----	3-9
Y	EP 0 396 124 A (SEARLE & CO) 7 November 1990 (1990-11-07) page 5, line 5-20; example 20 ----	3-9
Y	WO 96 20191 A (SANKYO CO ;NARUTO SHUNJI (JP); KOYAMA KAZUO (JP); UEDA YASUSHI (JP) 4 July 1996 (1996-07-04) abstract; table 2 -----	3-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 02/01192

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 3197479	A	27-07-1965	NONE	
GB 778823	A	10-07-1957	NONE	
FR 2499987	A	20-08-1982	JP 1048267 B JP 1592491 C JP 57139065 A BE 892145 A1 CH 648018 A5 DE 3205388 A1 FR 2499987 A1 HU 186036 B	18-10-1989 14-12-1990 27-08-1982 27-05-1982 28-02-1985 23-09-1982 20-08-1982 28-05-1985
EP 0548813	A	30-06-1993	AU 661527 B2 AU 3003492 A CA 2084531 A1 CZ 9203592 A3 EP 0548813 A1 FI 925737 A IL 104024 A JP 5262762 A MX 9207114 A1 NO 302522 B1 NZ 245439 A RU 2114111 C1 US 5434154 A ZA 9209445 A CN 1085556 A	27-07-1995 24-03-1994 20-06-1993 19-01-1994 30-06-1993 20-06-1993 15-04-1997 12-10-1993 01-07-1993 16-03-1998 26-07-1995 27-06-1998 18-07-1995 12-07-1993 20-04-1994
WO 9014084	A	29-11-1990	AU 644367 B2 AU 5720690 A BR 9007382 A CA 2056364 A1 CN 1047974 A EG 19554 A EP 0472628 A1 GR 90100369 A , B HU 60134 A2 HU 9400017 A3 IL 94411 A JP 5500207 T MW 6691 A1 WO 9014084 A1 NO 914468 A NZ 233697 A NZ 244997 A OA 9562 A PT 94074 A ZA 9003811 A	09-12-1993 18-12-1990 28-04-1992 18-11-1990 26-12-1990 29-06-1995 04-03-1992 10-10-1991 28-08-1992 28-09-1994 16-10-1996 21-01-1993 14-07-1993 29-11-1990 07-01-1992 20-12-1996 20-12-1996 31-01-1993 08-01-1991 27-03-1991
EP 0396124	A	07-11-1990	CA 2016027 A1 EP 0396124 A2 JP 3047123 A PT 93943 A US 5137910 A US 5229413 A	05-11-1990 07-11-1990 28-02-1991 08-02-1991 11-08-1992 20-07-1993
WO 9620191	A	04-07-1996	AU 4355296 A	19-07-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 02/01192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9620191	A	WO 9620191 A1	04-07-1996
		JP 8239362 A	17-09-1996